Lukas Smolej, MD, PhD, Charles University, Hradec Králové, Czech Republic, comments on the use of genomic testing in chronic lymphocytic leukemia (CLL) routine clinical practice, including TP53 and IGHV mutational status testing, explaining that their role in treatment decisions remains unclear. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
